RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+43%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$926M
AUM Growth
+$212M
(+30%)
Cap. Flow
-$15.3M
Cap. Flow
% of AUM
-1.65%
Top 10 Holdings %
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
24
Reduced
46
Closed
5
Top Buys
| 1 |
Gilead Sciences
GILD
|
$17.7M |
| 2 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$9.4M |
| 3 |
Baxter International
BAX
|
$8.18M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$8.1M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.8M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$13.9M |
| 2 |
MacroGenics
MGNX
|
$9.07M |
| 3 |
Esperion Therapeutics
ESPR
|
$8.61M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.71M |
| 5 |
Nektar Therapeutics
NKTR
|
$6.6M |
Sector Composition
| 1 | Healthcare | 94.86% |
| 2 | Communication Services | 1.03% |
| 3 | Energy | 0.07% |
| 4 | Technology | 0.06% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
26
DELISTED
Acceleron Pharma Inc.
XLRN
| $14.8M | 1.6% |
155,000
+85,000
| +121% | +$8.1M |
|
27
CVS Health
CVS
$93.2B
| $14.7M | 1.59% |
227,000
-33,000
| -13% | -$2.14M |
|
28
Boston Scientific
BSX
$159B
| $14.4M | 1.56% |
410,000
-155,000
| -27% | -$5.44M |
|
|
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $13.3M | 1.43% |
210,778
-29,222
| -12% | -$1.84M |
|
|
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
| $12.7M | 1.38% |
75,000
-10,000
| -12% | -$1.7M |
|
31
Merck
MRK
$209B
| $12.4M | 1.34% |
167,680
-5,240
| -3% | -$387K |
|
|
ITCI
32
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.2M | 1.32% |
475,000
-92,534
| -16% | -$2.38M |
|
33
Medtronic
MDT
$118B
| $12M | 1.3% |
130,780
| – | – |
|
|
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11.4M | 1.23% |
100,000
-30,000
| -23% | -$3.43M |
|
35
Cooper Companies
COO
$13.1B
| $11.3M | 1.23% |
160,000
+64,000
| +67% | +$4.54M |
|
36
LivaNova
LIVN
$3.06B
| $10.6M | 1.14% |
220,000
+30,000
| +16% | +$1.44M |
|
37
Adverum Biotechnologies
ADVM
$69M
| $10.4M | 1.13% |
50,000
-5,000
| -9% | -$1.04M |
|
38
Intuitive Surgical
ISRG
$158B
| $9.69M | 1.05% |
51,000
-18,000
| -26% | -$3.42M |
|
|
LVGO
39
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $9.4M | 1.02% |
+125,000
| New | +$9.4M |
|
40
Iovance Biotherapeutics
IOVA
$789M
| $9.33M | 1.01% |
340,000
-25,000
| -7% | -$686K |
|
41
Alnylam Pharmaceuticals
ALNY
$59.3B
| $9.2M | 0.99% |
62,095
-17,905
| -22% | -$2.65M |
|
|
42
Neurocrine Biosciences
NBIX
$13.6B
| $9.15M | 0.99% |
75,000
-55,000
| -42% | -$6.71M |
|
|
AERI
43
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $8.71M | 0.94% |
590,000
-130,000
| -18% | -$1.92M |
|
44
Xencor
XNCR
$589M
| $8.42M | 0.91% |
260,000
-40,325
| -13% | -$1.31M |
|
45
Edwards Lifesciences
EW
$47.5B
| $8.29M | 0.9% |
120,000
-51,000
| -30% | -$3.52M |
|
46
Dynavax Technologies
DVAX
$1.19B
| $8.21M | 0.89% |
925,534
-74,466
| -7% | -$660K |
|
|
47
Baxter International
BAX
$12B
| $8.18M | 0.88% |
+95,000
| New | +$8.18M |
|
|
48
Regeneron Pharmaceuticals
REGN
$59.9B
| $7.8M | 0.84% |
+12,500
| New | +$7.8M |
|
49
HCA Healthcare
HCA
$95.7B
| $7.28M | 0.79% |
75,000
-15,000
| -17% | -$1.46M |
|
50
Exact Sciences
EXAS
$9.74B
| $6.96M | 0.75% |
80,000
-24,300
| -23% | -$2.11M |
|